Showing results (31-40 of 134) with videos related to
Sort By:
Pageof 14
Epidemiology and Psychiatric Sciences|October 28, 2020
Preserving equipoise and performing randomised trials for COVID-19 social distancing interventionsIoana Alina Cristea, Florian Naudet, John P A IoannidisTherapie|May 25, 2020
[Data sharing policies of clinical trials funders in France]Pauline Rollando, Céline Parc, Florian Naudet, et al.International Journal of Methods in Psychiatric Research|September 17, 2013
Improving study design for antidepressant effectiveness assessmentFlorian Naudet, Bruno Millet, Jean Michel Reymann, et al.Health Research Policy and Systems|March 7, 2026
Gender disparities in securing national clinical research program (PHRC-N) funding in France: a retrospective analysis of the 2022 campaignSolène Mathieu, Constant Vinatier, Florian Naudet, et al.BMC Medicine|December 3, 2025
Concordance between European medicine agency good clinical practice inspections and medical literature: a meta-research surveyAlexandre Terré, Ondine Becker, John P A Ioannidis, et al.Journal of Periodontal Research|August 6, 2019
Clinical application of mesenchymal stem cells in periodontal regeneration: A systematic review and meta-analysisSolen Novello, Alexandre Debouche, Marie Philippe, et al.International Journal of Methods in Psychiatric Research|April 19, 2019
Power behind the throne: A clinical trial simulation study evaluating the impact of controllable design factors on the power of antidepressant trialsAstrid Chevance, Florian Naudet, Raphaël Gaillard, et al.BMJ Open|August 19, 2021
Status, use and impact of sharing individual participant data from clinical trials: a scoping reviewChristian Ohmann, David Moher, Maximilian Siebert, et al.Canadian Journal of Public Health = Revue Canadienne De Sante Publique|July 14, 2007
[Mass screening guidelines for prostate cancer: Should they be utilized in France?]Maxime Gignon, Alain Braillon, François-Xavier Chaine, et al.The International Journal of Risk & Safety in Medicine|May 28, 2026
Concerning the harm-benefit ratio of escitalopram for pediatric generalized anxiety disorder. A critical viewpoint on the evidence and approval processMartin Plöderl, Mark Horowitz, Florian Naudet, et al.Pageof 14